Phibro Animal Health Corporation

PAHC

US71742Q1067

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
16.78 ^USD	+31.81%		+28.58%	+44.91%

Apr. 29	Zoetis to Sell Medicated-Feed-Additive Portfolio to Phibro for $350 Million	DJ
Apr. 29	Zoetis to Sell Medicated Feed Additives Business to Phibro Animal Health for $350 Million	MT

Phibro Animal Health Corporation Reiterates Earnings Guidance for the Year Ending June 30, 2023

May 03, 2023 at 04:30 pm EDT

Phibro Animal Health Corporation reiterated earnings guidance for the year ending June 30, 2023. For the year, the company expects Net sales of $960 million - $1 billion, Net income of $34 million - $38 million, and Diluted EPS of $0.84 - $0.94.

Latest news about Phibro Animal Health Corporation

Zoetis to Sell Medicated-Feed-Additive Portfolio to Phibro for $350 Million	Apr. 29	DJ
Zoetis to Sell Medicated Feed Additives Business to Phibro Animal Health for $350 Million	Apr. 29	MT
Zoetis to sell medicated feed additive portfolio to Phibro in $350 mln deal	Apr. 28	RE
Phibro Animal Health Corporation entered into a definitive agreement to acquire Medicated feed additive product portfolio, certain water soluble products and related assets of Zoetis Inc. for approximately $350 million.	Apr. 27	CI
Transcript : Phibro Animal Health Corporation Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 04:35 PM	Mar. 12
Transcript : Phibro Animal Health Corporation Presents at Bank of America 2024 Animal Health Virtual Summit, Feb-29-2024 10:00 AM	Feb. 29
Transcript : Phibro Animal Health Corporation, Q2 2024 Earnings Call, Feb 08, 2024	Feb. 08
Earnings Flash (PAHC) PHIBRO ANIMAL HEALTH CORPORATION Posts Q2 EPS $0.33, vs. Street Est of $0.28	Feb. 07	MT
Earnings Flash (PAHC) PHIBRO ANIMAL HEALTH CORPORATION Reports Q2 Revenue $249.9M, vs. Street Est of $240.9M	Feb. 07	MT
Phibro Animal Health Corporation Reaffirms Earnings Guidance for the Fiscal Year 2024	Feb. 07	CI
Phibro Animal Health Corporation Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 07	CI
Phibro Animal Health Corporation Declares Quarterly Cash Dividend, Payable on March 27, 2024	Feb. 06	CI
Phibro Animal Health Corporation Announces Chief Financial Officer Changes, Effective February 9, 2024	Feb. 06	CI
Morgan Stanley Trims Price Target on Phibro Animal Health to $16 From $17, Maintains Equalweight Rating	Nov. 09	MT
Transcript : Phibro Animal Health Corporation, Q1 2024 Earnings Call, Nov 09, 2023	Nov. 09
Earnings Flash (PAHC) PHIBRO ANIMAL HEALTH CORPORATION Reports Q1 EPS $0.14, vs. Street Est of $0.23	Nov. 08	MT
Earnings Flash (PAHC) PHIBRO ANIMAL HEALTH CORPORATION Posts Q1 Revenue $231.3M, vs. Street Est of $242M	Nov. 08	MT
Phibro Animal Health Corporation Provides Consolidated Earnings Guidance for the Year Ending June 30, 2024	Nov. 08	CI
Phibro Animal Health Corporation Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 08	CI
Phibro Animal Health Defends Use of Swine Medicine Following FDA Move to Withdraw Approval	Nov. 07	MT
Phibro Animal Health Corporation Reiterates Safety of Mecadox and Intent to Defend its Use for Customers	Nov. 07	CI
Phibro Animal Health Corporation Declares Quarterly Cash Dividend, Payable on December 20, 2023	Nov. 06	CI
Phibro Animal Health Corporation Announces Chief Financial Officer Changes	23-09-06	CI
Phibro Animal Health CFO Damian Finio to Step Down; Richard Johnson to Serve as Interim CFO	23-09-05	MT
Morgan Stanley Adjusts Price Target on Phibro Animal Health to $17 From $18, Maintains Equal-Weight Rating	23-08-31	MT

Chart Phibro Animal Health Corporation

Duration

Period

More charts

Company Profile

Phibro Animal Health Corporation is a diversified animal health and mineral nutrition company. It develops, manufactures and markets a range of products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. It markets approximately 770 product lines in over 80 countries to approximately 4,000 customers. The Company has three segments. Animal Health segment develops, manufactures and markets about 270 product lines, including antibacterials, anticoccidials and related products; nutritional specialty products; and vaccines. Mineral Nutrition segment manufactures and markets approximately 420 formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries, predominantly in the United States.

Sector

Pharmaceuticals

Calendar

2024-05-07 - Q3 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Phibro Animal Health Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

16.78 USD

Average target price

10.75 USD

Spread / Average Target

-35.94%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Veterinary Drugs

	1st Jan change	Capi.
PHIBRO ANIMAL HEALTH CORPORATION	+44.91%	516M
ZOETIS INC.	-19.09%	72.39B
ELANCO ANIMAL HEALTH INCORPORATED	-8.93%	6.54B
BLUESTAR ADISSEO COMPANY	+21.38%	3.43B
VIMIAN GROUP AB	+1.52%	1.4B
JINYU BIO-TECHNOLOGY CO., LTD.	-16.99%	1.34B
VETOQUINOL SA	-3.81%	1.26B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-26.05%	1.2B
WUHAN KEQIAN BIOLOGY CO.,LTD	-12.71%	1.12B
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD.	-4.03%	990M

Veterinary Drugs